What one share of Ovid Therapeutics holds
Ovid is a biopharmaceutical company that is dedicated to developing small molecule medicines for brain disorders with significant unmet need. These potential medicines targeting the central nervous system (“CNS”) are designed to potentially halt the course of brain disease by quelling neuronal hyperexcitation and alleviating the most impactful patient symptoms.
Ovid Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.01 |
|---|---|
| Profit | −$0.28 |
| Cash and investments | $0.06 |
| Book value | $1.14 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2015 | — | −$1.36 | $0.00 | −$0.57 | — | $7.02 |
| 2016 | — | −$2.28 | $0.00 | −$1.81 | — | $5.01 |
| 2017 | — | −$3.35 | $0.00 | −$1.63 | — | $3.39 |
| 2018 | — | −$2.11 | $0.00 | −$1.85 | — | $1.57 |
| 2020 | — | −$1.39 | $0.00 | −$0.88 | — | $0.66 |
| 2021 | — | $1.76 | $0.00 | $1.74 | — | $2.55 |
| 2022 | $0.02 | −$0.77 | $0.02 | −$0.80 | — | $1.88 |
| 2023 | $0.01 | −$0.74 | $0.00 | −$0.65 | — | $1.24 |
| 2024 | $0.01 | −$0.37 | $0.00 | −$0.80 | — | $0.96 |
| 2025 | $0.10 | −$0.23 | $0.00 | −$0.51 | — | $1.00 |
Common questions about Ovid Therapeutics
How much does one share of Ovid Therapeutics earn?
Over the last 12 months, Ovid Therapeutics lost $0.28 for each share on $0.01 of sales.
Does Ovid Therapeutics pay a dividend?
Ovid Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Ovid Therapeutics’s book value per share?
Ovid Therapeutics’s book value is $1.14 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Ovid Therapeutics have?
Each share of Ovid Therapeutics has $0.06 of cash and investments, as of June 30, 2026.
Has Ovid Therapeutics bought back shares?
Ovid Therapeutics’s share count rose about 668% from 2015 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.